An analytical model is presented for predicting the transport and capture of therapeutic magnetic nanoparticles in the human microvasculature. The nanoparticles, with surface bound drug molecules, are injected into the vascular system upstream from malignant tissue, and are captured at the tumor site using a local applied magnetic field. The applied field is produced by a rare-earth cylindrical magnet positioned outside the body. An analytical expression is derived for predicting the trajectory of a particle as it flows through the microvasculature in proximity to the magnet. In addition, a scaling relation is developed that enables the prediction of the minimum particle radius required for particle capture. The theory takes into account the dominant magnetic and fluidic forces, which depend on the position and properties of the magnet, the size and magnetic properties of the nanoparticles, the dimensions of the microvessel, the hematocrit level of the blood, and the flow velocity. The model is used to study noninvasive drug targeting, and the analysis indicates that submicron particles can be directed to tumors that are several centimeters from the field source.
I. INTRODUCTION
Magnetic targeting of anticancer agents to malignant tissue using magnetic carrier particles can improve the effectiveness of the treatment while reducing its side effects. The growing interest in this therapy is due to rapid progress in the development of functionalized magnetic nanoparticles that are designed to target a specific tissue, and effect local chemo-, radio-, and genetherapy at a tumor site ͓1-4͔. In magnetic drug targeting, magnetic carrier particles with surface-bound drug molecules are injected into the vascular system upstream from the malignant tissue, and are captured at the tumor via a local applied magnetic field. Upon achieving a sufficient concentration, the drug molecules are released from the carriers by changing physiological conditions such as pH, osmolality, or temperature, or by enzymatic activity ͓5͔. The released drug is taken up by the malignant cells, and the magnetic carriers are ultimately processed by the body. Since the therapeutic agents are localized to regions of diseased tissue, higher dosages can be applied which enables more effective treatment. This is in contrast to conventional therapy in which a drug is distributed in a systemic fashion throughout the body, which can have a deleterious affect on healthy tissue Magnetic drug targeting has been studied primarily using surface tumors ͓4,5͔ and small animal models: rabbits ͓5͔, swine ͓6,7͔, and rats ͓8,9͔. Clinical trials have produced encouraging results that range from the permanent remission of squamous cell carcinoma in New Zealand White Rabbits ͓5͔, to the effective treatment of breast cancer in humans ͓10-12͔.
In addition to the clinical trials, theoretical research has been conducted to predict magnetic drug targeting for various applications. In most of this work numerical methods such as finite element analysis ͑FEA͒ are used to calculate the magnetic field distribution. The numerical field solution is used in the equations of motion to predict the particle trajectory, which is based on Newtonian dynamics ͓13-16͔. The fluidic force on the particle is usually obtained using Stokes' law for the drag on a sphere in a laminar flow field. As a further simplification, the blood flow is often modeled as two-dimensional laminar flow of Newtonian fluid between stationary parallel plates. While these studies are useful for predicting viable operating parameters for magnetic targeting systems, there is a need for a more rigorous theory, preferably one that does not rely on either a numerical field solution, which is awkward for parametric analysis, or a two dimensional flow approximation, which is a poor approximation for flow through a cylindrical vessel.
In this paper we present an analytical model for predicting the transport and capture of magnetic nanoparticles in the microvasculature. Magnetophoretic control of the particles is provided by a rare-earth cylindrical magnet positioned outside the body as shown in Fig. 1 . The magnet is assumed to be of infinite extent, with its axis orthogonal to the blood flow. It is magnetized perpendicular to its axis, and produces a nonuniform field distribution in nearby tissue. The magnetic force that it produces is based on an analytical expression for the field distribution in the microvessel, combined with a linear magnetization model for the magnetic response of particles. The model takes into account the dimensions and polarization of the magnet, the magnetization and size of the particles, the dimensions of the microvessel, the hematocrit level of the blood, and the flow velocity. The fluidic analysis is based on the assumption of laminar blood flow through a cylindrical microvessel, and the effect of the blood cells is taken into account via use of an effective bulk viscosity. The analytical force expressions are used in the equations of motion, which are solved analytically to predict particle trajectories within a microvessel, parametrically as a function of the variables described above. In addition, a scaling relation is developed that enables the prediction of the minimum particle radius required for particle capture. The model is used to study particle capture, and the analysis demonstrates the viability of using noninvasive magnetophoretic control of magnetic nanoparticles to effect drug delivery to tumors that are a few centimeters from the field source. The model is ideal for parametric optimization of novel magnetophoretic systems for drug delivery, and can be of substantial benefit in improving the effectiveness of magnetic targeting apparatus for clinical research.
II. THEORY

A. Equations of motion
Magnet particle transport in the microvasculature is governed by several factors including ͑a͒ the magnetic force due to all field sources, ͑b͒ viscous drag, ͑c͒ particle-blood-cell interactions, ͑d͒ inertia, ͑e͒ buoyancy, ͑f͒ gravity, ͑g͒ thermal kinetics ͑Brownian motion͒, ͑h͒ particle-fluid interactions ͑perturbations to the flow field͒, and ͑i͒ interparticle effects that include magnetic dipole interactions, electric doublelayer interactions, and van der Walls force. In this paper, we take into account the dominant magnetic and viscous forces, and the particle-blood-cell interactions via use of an effective viscosity. We ignore all other forces, which are second order. For example, the gravitational and buoyant forces F g and F b on a 0.5 m ͑R p = 250 nm͒ iron-oxide ͑Fe 3 O 4 , = 5000 Kg/ m 3 ͒ particle in water are F g = 3.2ϫ 10 −3 pN and F b = 0.641ϫ 10 −3 pN. These are an order of magnitude smaller than the magnetic force. A similar analysis applies to the inertial force m p a p , which we discuss in more detail below. We assume that we are dealing with dilute particle suspensions in which the particle volume concentration is small, i.e., c Ӷ 1 ͑c is the total volume occupied by the particles per unit volume of fluid͒. In this case, interparticle effects and particle-fluid interactions can also be neglected.
We predict particle motion using Newton's law:
where m p and v p are the mass and velocity of the particle, and F m and F f are the magnetic and fluidic forces, respectively. As noted above, and discussed in more detail later, the inertial term m p dv p dt is small and could be neglected. The magnetic force is obtained using the "effective" dipole moment method in which the magnetized particle is replaced by an "equivalent" point dipole with a moment m p,eff ͓17͔. The force on the dipole ͑and hence on the particle͒ is given by
where f is the permeability of the transport fluid, m p,eff is the effective dipole moment of the particle, and H a is the ͑externally͒ applied magnetic field intensity at the center of the particle, were the equivalent point dipole is located. If the particle is in free space, m p,eff = V p M p and Eq. ͑2͒ reduces to the usual form
where V p and M p are the volume and magnetization of the particle, respectively. The fluidic force is obtained using the Stokes' approximation for the drag on a sphere ͓18͔,
where and v f are the viscosity and the velocity of the fluid, respectively. At this point, we digress briefly to discuss the limitations of the Newtonian approach. Equation ͑1͒ does not take into account Brownian motion, which can influence particle capture when the particle diameter D p is sufficiently small. Gerber et al. ͓19͔ have developed the following criterion to estimate this diameter:
where ͉F͉ is the magnitude of the total force acting on the particle, k is the Boltzmann constant, and T is the absolute temperature. In order to apply Eq. ͑4͒, one needs to estimate ͉F͉. If the magnetic field source is specified, one can estimate ͉F͉ for a given particle by taking a spatial average of the force on the particle over the region of interest. Gerber et al. have studied the capture of Fe 3 O 4 particles in water using a single magnetic wire, and have estimated the critical particle diameter for this application to be D c,p ϵ kT / ͉F͉ =40 nm ͑i.e., ͉F͉ = 0.1 pN͒ ͓19͔. For particles with a diameter below D c,p ͑which is application dependent͒ one solves an advection-diffusion equation for the particle number density n͑r , t͒, rather than the Newtonian equation for the trajectory of a single particle. The behavior of n͑r , t͒ is governed by the following equation ͓19-21͔:
where J = J D + J F is the total flux of particles, which includes a contribution J D =−D ١ n͑r , t͒ due to diffusion, and a contribution J F = vn͑r , t͒ due to the action of all external forces. Equation ͑5͒ is often written in terms of the particle volume concentration c͑r , t͒, which is related to the number density, c͑r , t͒ =4R p 3 n͑r , t͒ / 3. The diffusion coefficient D is given by the Nernst-Einstein relation D = kT, where =1/͑6R p ͒ is the mobility of a particle of radius R p in a fluid with viscosity ͑Stokes' approximation͒. The drift velocity also depends of the mobility v͑r͒ = F͑r͒, where F͑r͒ = F m ͑r͒ + F f ͑r͒ +¯is the total force on the particle. Thus Eq. ͑5͒ can be rewritten as
͑6͒
B. Magnetic force
To determine the magnetic force, we need a model for the magnetic response of the particle. We use a linear magnetization model with saturation. Specifically, below saturation,
where p and p = p / 0 − 1 are permeability and susceptibility of the particle. Above saturation M p = M sp , where M sp is the saturation magnetization of the particle. In Eq. ͑7͒, H in = H a − H demag is the field inside the particle, which is different than the ͑externally͒ applied field, because the magnetization of the particle itself gives rise to a selfdemagnetization field H demag that opposes H a ͑see pp. 23-27 in Ref. ͓22͔͒. For example, for a uniformly magnetized sphere with magnetization M p in free space, H damag = M p 3 is the field inside the sphere due to the "magnet change" m = M p · n at its surface ͑n is the unit vector normal to the surface͒. According to the linear model, the magnetic field intensity required to saturate the particle is H in,sat = M sp / p .
We now determine the magnetic force using the "effective" dipole moment method as described by Jones ͓17͔. The effective moment of the particle ͑the equivalent point dipole moment͒ is obtained as follows: ͑i͒ first solve the magnetostatic boundary value problem for the particle ͑sphere͒ immersed in a fluid, with its magnetization M p parallel to the applied field; and then ͑ii͒ determine the equivalent point dipole moment m p,eff that, when positioned at the center of the particle, produces the same field distribution outside the particle as that produced by the particle itself.
The fields inside and outside the particle can be represented in terms of scalar potentials, ⌽ in =−ٌH in and ⌽ out = −ٌH out where
In Eqs. ͑8͒ and ͑9͒, ͑r , ͒ are spherical polar coordinates taken with respect to the center of the particle, with the z axis in the direction of the applied field. It is instructive to note that the magnitude of the field intensity inside the particle is
The unknown coefficients C in and C out are obtained from the boundary conditions for the potential ⌽ in ͑r , ͒ = ⌽ out ͑r , ͒, and for the normal component of
and
Now, the potential due to a point dipole of magnitude m p,eff is of the form
Thus by comparing Eqs. ͑9͒ and ͑12͒ we find that the magnitude of the "equivalent" dipole for the particle is m p,eff =4C out , and from Eq. ͑11͒ we have
Since H in = C in , we also find that
Now, if the particle is below saturation, M p = p H in . We substitute this into Eqs. ͑13͒ and ͑14͒ and obtain
and FIG. 2. Geometry and reference frame for analysis: ͑a͒ coordinate systems and reference frames, ͑b͒ magnetic flux lines for a cylindrical magnet, cross section of microvessel with reference frame.
where V p is the volume of the particle. Finally, we substitute Eq. ͑17͒ into Eq. ͑2͒ and obtain the force on the magnetized particle in a fluid of permeability f ,
Now, when ͉ f ͉ Ӷ 1 ͑i.e., f Ϸ 0 ͒, Eq. ͑18͒ reduces to
It also follows that
and that
If we take saturation into account, the effective dipole moment can be written as
where
and H a = ͉H a ͉.
In this analysis, the magnet is assumed to be of infinite extent in the y direction, and therefore the y components of the magnetic field and force are zero, i.e., 
͑27͒
To evaluate F m ͑x , y͒ we need an expression for the field distribution H a ͑x , y͒.
C. Magnetic field and force of a cylindrical magnet
The source magnet has a radius R mag and is centered with respect to the origin in the xЈ-zЈ plane as shown in Fig. 2 We convert these to Cartesian coordinates,
and obtain the field gradients,
͑35͒
For the force analysis, we rewrite Eqs. ͑32͒-͑35͒ in terms of the ͑x , z͒ coordinates that are fixed with respect to the microvessel ͓Fig. 2͑a͔͒. Specifically, we transform Eqs. ͑30͒-͑35͒, substitute into Eqs. ͑26͒ and ͑27͒, and obtain
The force component that governs particle capture is F mx , and from Eq. ͑36͒ we find that it is always attractive ͑to-wards the magnet͒ as d ӷ x.
D. Fluidic force
To evaluate the fluidic force in Eq. ͑3͒ we need an expression for the fluid velocity v f in a microvessel. We choose a coordinate system with the z axis along the axis of the vessel, and with the x-y plane centered with respect to its cross section. We assume fully developed laminar flow parallel to the z axis,
where v f is the average axial fluid velocity in a microvessel of radius R v . We substitute Eq. ͑38͒ into Eq. ͑3͒ and obtain the fluidic force components
To evaluate Eqs. ͑39͒-͑41͒ we need an expression for blood viscosity . Blood is a suspension of red and white blood cells ͑erythrocytes and leukocytes͒, and platelets in plasma. Blood plasma ͑absent the cells and platelets͒ is an incompressible Newtonian fluid with a viscosity plasma = 0.0012 N s / m 2 . Red blood cells have a biconcave discoid shape with a diameter of 6 -8 m, and a thickness of 2 m. These cells account for approximately 99% of the particulate matter in blood. The hematocrit, which is the percentage by volume of packed red blood cells in a given sample of blood, is nominally 40-45 %. The rheological properties of blood in the microvasculature depend on many factors including the diameter of the blood vessel, the flow velocity, the hematocrit, the finite size of the blood cells, their elastic properties, the aggregation and deformation of the blood cells, etc. ͓23͔. A rigorous prediction of these properties is beyond the scope of this work. Here, we use an analytical empirically based expression for the viscosity in vivo that applies for medium to high shear rates,
Specifically, the apparent blood viscosity ͑relative to that of plasma͒ can be estimated using ͓24͔ 
͑45͒
Parametric plots of rel are shown in Fig. 3 . More extensive plots can be found in Ref. ͓24͔ . Notice that rel decreases with vessel diameter, and obtains a minimum value for diameters between 10 and 100 m. This is known as the Fahraeus-Lindqvist effect and is due to the fact that blood cells are displaced towards the axis of a narrow vessel as they pass through it thereby creating a cell-depleted region near the wall of the vessel and a relatively fast moving core of cells near the center, which results in a decrease in apparent viscosity. It is important to note that Eq. ͑43͒ gives the viscosity relative to that of the plasma. Thus the effective blood viscosity in Eqs. ͑39͒-͑41͒ is given by = rel plasma .
͑46͒
FIG. 3. Relative apparent viscosity vs blood vessel diameter and hematocrit. ANALYTICAL MODEL OF MAGNETIC NANOPARTICLE¼
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061919-5 E. Analytical equation for particle motion
The equations of motion can be written in component form by substituting Eqs. ͑36͒, ͑37͒, and ͑39͒-͑41͒ into Eq. ͑1͒,
Since the magnetic force has no y-component, we can simplify the analysis by assuming that there is no motion in the y-direction, which means that we ignore Eq. ͑48͒, and focus instead on Eqs. ͑47͒ and ͑49͒ with y = 0, which govern motion in the x-z plane. These equations can be further simplified. To this end, we scale the distance d ͑from the magnet to the microvessel͒ in terms of the magnet radius, d = ͑1 + ␣͒R mag , and introduce the dimensionless parameters,
Using these definitions, Eqs. ͑47͒ and ͑49͒ can be rewritten in nondimensional form,
For practical applications, it is easy to verify that m Ӷ 1, which implies that inertial effects are negligible. Thus we can neglect the first term in Eq. ͑51͒. Similarly, ␤ Ӷ 1, which implies that viscous drag dominates motion in the z direction. Thus we also ignore the first term on the right-hand side of Eq. ͑52͒, and Eqs. ͑51͒ and ͑52͒ reduce to
We divide Eq. ͑56͒ by Eq. ͑57͒,
and integrate Eq. ͑58͒ to obtain an analytical equation for the particle trajectory, ͩx− 
where x 0 and z 0 are the initial normalized coordinates of the particle. Note that we have ignored the spatial dependence of f͑H a ͒ in the parameter C. This amounts to assuming that the particles are either magnetically biased below saturation, or magnetically saturated, throughout their range of motion. These conditions can be tested by evaluating the magnitude of the magnetic field along the axis of the microvessel, and applying Eq. ͑23͒. For noninvasive drug targeting the particles are typically biased below saturation. Equation ͑59͒ is an analytical expression for predicting particle motion within a microvessel, and is one of our key results. It is convenient to rewrite it as 
can be solved explicitly for x in terms of z. Specifically, for a given value of z it has three roots x 1 , x 2 , and x 3 , one of which is physical,
͑64͒
The physical solution of Eq. ͑60͒, which we denote as x͑z͒, is real-valued with ͉x͉ ഛ 1 and satisfies the initial condition x͑z 0 ͒ = x 0 . We use Eq. ͑60͒ to study particle capture. A particle is captured when its position equals the radius of the blood vessel, i.e., when x 2 = 1. Let z c denote the normalized point of capture, then x 2 ͑z c ͒ =1, or x͑z c ͒ = ± 1. If a particle is captured, a unique physical solution will exist for z 0 ഛ z ഛ z c . If the particle is too small to be captured, a unique physical solution with ͉x͑z͉͒ Ͻ 1 will exist for z 0 ഛ z Ͻϱ.
We can estimate the conditions for particle capture as follows. First, we obtain a bound for Eq. ͑58͒, ͩx−
͑67͒
Next, assume that the particle starts at top of the blood vessel ͑farthest from the magnet͒ at x 0 = 1, which gives ͩx−
Now, evaluate Eq. ͑68͒ for the condition of particle capture ͑x =−1͒, and obtain
Lastly, we assume that the particle has a susceptibility much greater than that of blood ͑ p ӷ f ͒, and that it is magnetically biased below saturation, which gives
It is important to note that the scaling relation ͑71͒ is based on the assumption that z 0 =−ϱ. For practical applications this means the particle starts far enough upstream where the magnetic field and force are negligible. Equation ͑71͒ can be used determine viable values for the parameters R p , p , M s , and ␣, for achieving efficient particle capture.
III. RESULTS
We use Eq. ͑60͒ to study the transport and capture of therapeutic magnetite ͑Fe 3 O 4 ͒ nanoparticles in the microvasculature. For this analysis, we assume that the susceptibility of blood is essentially that of free space, but it is important to note that in general, the susceptibility of the suspending medium can have a significant effect on the magnetic force ͓25-27͔. Fe 3 O 4 particles are biocompatible, and have a density p = 5000 kg/ m 3 , and a saturation magnetization M sp = 4.78ϫ 10 5 A / m. We adopt a magnetization model for Fe 3 O 4 described by Takayasu et al. ͓20͔ , which is consistent with Eq. ͑23͒ when p ӷ 1,
According to this model, if the particle is below saturation then is measured with respect to the applied field, rather than the internal field ͓28͔. Throughout this analysis we use the Cartesian coordinate system fixed to the microvessel as shown in Fig. 2 ͑i.e., the z axis is along the axis of the microvessel͒. First, we use Eqs. ͑30͒ and ͑31͒, and Eqs. ͑36͒ and ͑37͒ to compute the magnet field and force along the axis of the microvessel ͑−4R mag ഛ z ഛ 4R mag ͒ which is located 1.5 cm from the surface of a rare-earth NdFeB magnet. The magnet is 4 cm in diameter ͑R mag = 2.0 cm, d = 3.5 cm͒ with a magnetization M s =1ϫ 10 6 A/m ͑remanence B r = 1.256 T͒. The force is computed on a Fe 3 O 4 nanoparticle with a radius R p = 100 nm. Plots of B x , B z , F mx , and F mz , along with corresponding data obtained using finite element analysis ͑FEA͒, are shown in Figs. 4 and 5. The FEMLAB program from COMSOL was used for the FEA. Notice that B x obtains its maximum value at the center of the magnet ͑z / R mag =0͒, whereas B z peaks at the edges ͑z / R mag = ±1͒, and alternates in sign from one edge to the other. The horizontal component of the magnetic force F mz has a profile similar to B z , but with an opposite polarity of sign ͑Fig. 5͒. Thus, as a particle moves horizontally above the magnet ͑left-to-right͒ it experiences a horizontal acceleration as it passes the leading edge of the magnet, followed by a deceleration as it passes the trailing edge. The vertical force F mx , which is responsible for particle capture, is always negative ͑attractive towards the magnet͒, and is strongest above the center of the magnet ͑z / R mag =0͒. Next, we study particle transport through a microvessel. To demonstrate the theory, we choose a microvessel with a radius R v =75 m, and an average flow velocity v f = 15mm/ s ͑shear rate v f / D v = 100/ s͒. For the calculation of effective viscosity, we assume plasma = 0.0012 N s / m 2 , and a hematocrit of 45%. We use the same magnet parameters above. The initial conditions for the particles are as follows. They start on the axis of the microvessel ͑x 0 = ȳ 0 =0͒, far enough upstream so that the magnetic force is initially negligible, at z͑0͒ =−4R mag ͓z 0 =−4/͑1+␣͔͒. Thus they have an initial velocity equal to the axial flow velocity ͑i.e., v x ͑0͒ =0, v y ͑0͒ = 0, and v z ͑0͒ =2v f =30 mm/s͒.
We predict the trajectories of five different sized Fe 3 O 4 particles: R p = 150, 200, 250, 300, 350 nm, for a range of magnet-to-vessel distances d = ͑1+␣͒R mag where ␣ = 0.25, 0.5, and 0.75. In these plots the radial position r = ͉x͉ of the particle is normalized with respect to the microvessel radius R v , and the axial position z is normalized with respect to the magnet radius R mag . The ␣ = 0.25 trajectory, along with the magnetic geometry, is shown in Fig. 6 . This plot shows that all the particles except the smallest ͑R p = 150 nm͒ are captured by the magnet when the microvessel is 0.5 cm from the surface of the magnet ͓d = ͑1+␣͒R mag = 2.5 cm͔. The ␣ = 0.5 and 0.75 trajectories are shown in Fig. 7 . Notice that as the distance from the magnet increases, fewer particles are captured, and at d = 3.5 cm ͑␣ = 0.75͒ only the largest particle ͑R p = 350 nm͒ is captured. This is because the magnetic force is proportional to the volume of the particle ͑V p ϰ R p 3 ͒. Hence larger particles experience a stronger capture force, and can be captured at farther distances. We study the particle size and capture dependency in more detail by analyzing the trajectories of five larger Fe 3 O 4 particles: R p = 400, 450, 500, 550 and 600 nm, with the microvessel farther from the magnet, i.e., ␣ = 1.0 and 1.25 ͑Fig. 8͒. As before, larger particles are captured at farther distances.
We can estimate the minimum particle radius that will result in capture using Eq. ͑71͒ The minimum capture radius depends on the initial position x 0 , ȳ 0 , and z 0 of the particle. As for the z 0 dependence, the derivation of the inequality Eq. ͑71͒ is based on the assumption that z 0 =−ϱ. For practical applications this means the particle starts far enough upstream where the magnetic field and force are negligible. From our analysis above, this occurs when z 0 Ͻ −4R mag , or z 0 Ͻ −4 / ͑1+␣͒. In the following, we assume that this condi- tion is satisfied. Now, for particles that start at the top of the microvessel ͑x 0 =1, ȳ 0 =0͒, farthest from the magnet, we have
A similar analysis applies to particles that start on the axis of the microvessel ͑x 0 =0͒, and yields
To obtain Eqs. ͑73͒ and ͑74͒, we have used p / ͑ p +3͒Ӎ1. We evaluate these equations for a range of values 0.25ഛ ␣ ഛ 2.5 ͑Fig. 9͒. The values obtained for the x 0 = 0 case are consistent with the trajectory analysis above. Specifically, from Eq. ͑74͒ we find that the minimum particle radius required to ensure particle capture is R p,capture = 156 225, 305, 400, and 505 nm for ␣ = 0.25, 0.5, 0.75, 1.0, and 1.25, respectively. From the trajectory analysis, we found that particles with a corresponding radius of R p = 150, 200, 300, 400, and 500 nm or below, were not captured, which is consistent. Lastly, note from Eq. ͑73͒ that the minimum particle radius required for capture does not depend on the distance to the capture site per se, but rather on the ratio d 2 / R mag 2 through the term ͑1+␣͒ 2 . Specifically, let d tumor denote the distance of the tumor inside the body, then d tumor = d − R mag = ␣R mag . Thus to effect particle capture at d tumor , we first compute ␣ = d tumor / R mag , and then use Eq. ͑73͒ to compute the minimum particle radius needed for capture. This would seem to imply that noninvasive magnetic drug targeting could be implemented at arbitrary depths in the body by simply choosing a larger magnet. However, recall that the initial position of the particle z 0 needs to be far upstream, outside the influence of the magnet, which occurs when z 0 Ͻ −4R mag . Thus, as R mag increases, the particles need to be injected at a distance that might not be practical. Moreover, R mag is limited to several centimeters for practical rare-earth magnets, and this sets a practical upper limit for d tumor .
IV. CONCLUSION
We have developed an analytical model for predicting the transport and capture of magnetic nanoparticles in the human microcvasulature. The theory applies to noninvasive therapy in which the magnetophoretic control is provided by a cylindrical magnet positioned outside the body. It takes into account the dominant magnetic and fluidic forces that govern particle motion, and is well suited for parametric analysis of practical drug delivery systems for anticancer treatment. We have used the model to study drug delivery, and our results indicate that malignant tissue can be targeted several centimeters within the body using submicron Fe 3 O 4 particles. The model developed herein is well suited for the design and optimization of novel magnetophoretic drug targeting apparatus. 
